← Back to Search
Phase 3 Study Of The Multidrug Resistance Modulator PSC-833 In Previously Untreated Patients 60 Years Of Age And Older With Acute Myeloid Leukemia: Cancer And Leukemia Group B Study 9720.
M. Baer, S. George, R. Dodge, Kieran L. O’Loughlin, H. Minderman, M. Caligiuri, J. Anastasi, B. Powell, J. Kolitz, C. Schiffer, C. Bloomfield, R. Larson
Published 2002 · Medicine
Save to my Library
Download via 🐼 PaperPanda Download via oaDOI Download via OAB Download via LibKey Download via Google Google ScholarAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
The Cancer and Leukemia Group B conducted a phase 3 trial of the P-glycoprotein modulator PSC-833 in untreated acute myeloid leukemia patients aged 60 years and older. Patients were randomized to 1 of 2 regimens, with doses determined in a prior phase 1 study, consisting of cytarabine 100 mg/m(2)/d by 7-day infusion, with daunorubicin 60 mg/m(2) and etoposide 100 mg/m(2) daily for 3 days (ADE), or daunorubicin 40 mg/m(2) and etoposide 60 mg/m(2) for 3 days with PSC-833, 2.8 mg/kg over 2 hours, and then 10 mg/kg/d by 3-day infusion (ADEP). The ADEP arm was closed after randomization of 120 patients (61 to ADE and 59 to ADEP) because of excessive early mortality. Rates of complete remission, nonresponse, and death were 46%, 34%, and 20% for ADE, versus 39%, 17%, and 44% for ADEP (P =.008). Nevertheless, disease-free survival (median 7 vs 8 months; P =.38) and overall survival (approximately 33% alive at 1 year) did not differ and were similar to historical results. Although the number of patients was limited, ADE patients whose pretreatment cells exhibited PSC-833-modulated dye efflux in vitro (n = 22) had worse outcomes than those without efflux (n = 11) (complete remission, nonresponse, and death rates of 41%, 41%, and 18%, compared with 91%, 9%, and 0%; P =.03), but with ADEP outcomes were nearly identical. Moreover, for patients with PSC-833-modulated efflux, median disease-free survival was 5 months with ADE and 14 months with ADEP (P =.07). Further modulation trials in older patients must await the design of less-toxic regimens.
This paper references
Nonparametric Estimation from Incomplete Observations
E. Kaplan (1958)
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.
R. Peto (1977)
Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources.
I. T. Young (1977)
A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables
C. Mehta (1983)
Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.
J. Bennett (1985)
posed revised criteria for the classification of acute myeloid leukemia : a report of the French - American - British Group
JM Bennett (1985)
Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein.
W. Dalton (1986)
Applied Logistic Regression
D. Hosmer (1989)
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.
B. Cheson (1990)
Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group.
J. Bishop (1990)
Etoposide in acute nonlymphocytic leukemia
JF Bishop (1990)
In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.
D. Bösch (1991)
Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO)
J. Bennett (1991)
ISCN 1991 : guidelines for cancer cytogenetics : supplement to An international system for human cytogenetic nomenclature : recommendations of the Standing Committee on Human Cytogenetic Nomenclature, Subcommittee on Cancer Cytogenetics
F. Mitelman (1992)
Pharmacologic interactions between the resistance‐modifying cyclosporine sdz psc 833 and etoposide (VP 16–213) enhance In Vivo cytostatic activity and toxicity
R. Keller (1992)
Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.
A. List (1993)
A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group B.
R. Weiss (1993)
Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia.
D. Ross (1993)
Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.
R. Mayer (1994)
A phase 1 trial of doxorubicin (D) and PSC833: a modulator of multidrug resistance (MDR)
C Erlichman (1994)
Recom - mendations for the use of hematopoietic colony - stimulating factors : evidence - based , clinical practice guidelines
RB Weiss (1994)
A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).
J. Rowe (1995)
Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.
R. Stone (1995)
ISCN 1995 : an international system for human cytogenetic nomenclature (1995) : recommendations of the International Standing Committee on Human Cytogenetic Nomenclature : Memphis, Tennessee, USA, October 9-13, 1994
F. Mitelman (1995)
Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia
R. Stone (1995)
Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases.
C. Leith (1995)
DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux.
H. Minderman (1996)
Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
P. Sonneveld (1996)
Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.
D. Boote (1996)
Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study.
E. Solary (1996)
Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.
C. Leith (1997)
Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein.
J. J. Starling (1997)
A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.
G. Giaccone (1997)
Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.
S. Kornblau (1997)
Dose-finding study of PSC833, a novel MDR reversing agent, with daunorubicin and ara-C in untreated elderly patients with acute myeloid leukemia [abstract
P Sonneveld (1997)
Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing
N. Meropol (1998)
A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031).
J. Godwin (1998)
A doubleblind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study
J Godwin (1998)
Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia
M. Tallman (1999)
Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar)
R. Advani (1999)
Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.
C. Leith (1999)
Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSCMEC) vs. MEC: randomized phase 3 trial
P Greenberg (1999)
Parallel phase 1 trials of multi-drug resistance (MDR) modulation with PSC-833 (PSC) in untreated patients with acute myeloid leukemia (AML) 60 years old: preliminary results of CALGB 9621 [abstract
JE Kolitz (1999)
Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia.
G. Dahl (2000)
Novel mechanisms of drug resistance in leukemia
D. Ross (2000)
P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.
U. Tidefelt (2000)
P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway.
M. Pallis (2000)
A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617.
T. Chauncey (2000)
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.
H. Ozer (2000)
Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.
R. Dorr (2001)
Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re‐induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML‐R trial
J. A. Liu Yin (2001)
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.
A. List (2001)
Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin.
R. Peck (2001)
Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia
G. Visani (2001)
Treat - ment of refractory / relapsed AML with PSC 833 plus mitoxantrone , etoposide , cytarabine ( PSC - MEC ) vs . MEC : randomized phase 3 trial ( E 2995 ) [ abstract ]
P Greenberg (2001)
Pre-treatment cytogenetics predict initial induction success and overall survival in adult patients with de novo acute myeloid leukemia: results from CALGB 8461 [abstract
JC Byrd (2001)
Mitoxantrone, etoposide, and cytarabine plus cyclosporine for PHASE 3 STUDY OF PSC-833 IN AML
MS Tallman (2002)
Response to ‘comparison of “sequential” versus “standard” chemotherapy as re‐induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (aml): results of the uk medical research council aml‐r trial’
B. Smith (2003)
Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo
K. Speeg (2004)
This paper is referenced by
Drug transporters in the development of multidrug resistance in colorectal cancer
K. To (2020)
Role of ATP-Binding Cassette Transporter Proteins in CNS tumors: Resistance-based perspectives and clinical updates.
M. Asif (2020)
Benchmarking treatment effects for patients over 70 with acute myeloid leukemia: A systematic review and meta-analysis.
T. Reljic (2020)
Integrating evolutionary dynamics into cancer therapy
R. Gatenby (2020)
Paclitaxel-loaded polypeptide-polyacrylamide nanomicelles overcome drug-resistance by enhancing lysosomal membrane permeability and inducing apoptosis.
S. Abbasi (2020)
A cell-based high-throughput screen identifies inhibitors that overcome P-glycoprotein (Pgp)-mediated multidrug resistance
Rida Zahra (2020)
Future Therapies for Malignant Brainstem Tumors
Z. Zhou (2020)
The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP
Sophie E B Ambjørner (2020)
Brainstem Tumors: Diagnosis and Management
G. Jallo (2020)
The Evolving AML Genomic Landscape: Therapeutic Implications.
S. Horibata (2020)
Novel 3,4-Dihydroisocoumarins Inhibit Human P-gp and BCRP in Multidrug Resistant Tumors and Demonstrate Substrate Inhibition of Yeast Pdr5
J. Sachs (2019)
Oligomeric proanthocyanidins (OPCs) from grape seed extract suppress the activity of ABC transporters in overcoming chemoresistance in colorectal cancer cells.
P. Ravindranathan (2019)
Acute Myeloid Leukemia in Older Adults
K. P. Loh (2019)
Drug repurposing to overcome resistance to various therapies for colorectal cancer
W. Fong (2019)
Significance of ABC Transporters in the Treatment of Intrinsically Resistant Acute Myeloid Leukemia
S. Horibata (2019)
Bioenergetic coupling in P-glycoprotein: determining the relative position, topography and role of transmembrane helices six and twelve
Carey Hulyer (2018)
Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia
D. Papaioannou (2017)
Novel strategies to prevent the development of multidrug resistance (MDR) in cancer.
Jing-lu Wang (2017)
Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study.
Yi-jun Wang (2017)
Genomics of Acute Myeloid Leukemia
Z. Ahmed (2017)
Expression of multidrug resistance protein P-glycoprotein in correlation with markers of hypoxia (HIF-1α, EPO, EPO-R) in invasive breast cancer with metastasis to lymph nodes
A. Badowska-Kozakiewicz (2017)
PXR IN BRAIN: NOVEL METHODS TO CHARACTERIZE ITS BIOLOGY
Xunan Shen (2017)
Systemic Treatment of Acute Myeloid Leukemia (AML)
A. Schuh (2016)
Thiosemicarbazones Target Multiple Resistance Pathways in Cancer
A. Stacy (2016)
Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly.
H. Klepin (2016)
Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia
B. Bhatnagar (2016)
Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance.
Shizhu Chen (2016)
Treatment and prognostic assessment of acute myeloid leukemia
B. R. Nandeesh (2016)
P-gp Inhibitors: A Potential Tool to Overcome Drug Resistance in Cancer Chemotherapy
Ankit Jain (2016)
The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade.
Rishil J. Kathawala (2015)
Esters of the Marine-Derived Triterpene Sipholenol A Reverse P-GP-Mediated Drug Resistance
Yongchao Zhang (2015)
Chamaejasmin B exerts anti-MDR effect in vitro and in vivo via initiating mitochondria-dependant intrinsic apoptosis pathway
Y. Wang (2015)See more